{"id":4378,"date":"2017-06-25T18:42:27","date_gmt":"2017-06-25T22:42:27","guid":{"rendered":"http:\/\/www.ackc.org\/?p=4378"},"modified":"2017-06-25T18:42:27","modified_gmt":"2017-06-25T22:42:27","slug":"for-patients-with-cardiovascular-diseases","status":"publish","type":"post","link":"https:\/\/www.ackc.org\/jayedit\/for-patients-with-cardiovascular-diseases\/","title":{"rendered":"For patients with cardiovascular diseases"},"content":{"rendered":"<p>The site <a href=\"https:\/\/cialweb.com\/\">ww.cialweb.com<\/a> presents a new article dedicated to the issue of prescribing phosphodiesterase type 5 inhibitors against erectile dysfunction (ED) for patients with cardiovascular diseases. In this large study, the papers of Shabber Abbas, BS, and Jacqueline Lanoix, PhD were used. Dr. Nehra, a consultant for the pharmaceutical concern Pfizer, left his notes about this study.<br \/>\nThe article contains detailed consideration of the intake of PDE-5 inhibitors against ED in patients with hypertension, dyslipidemia, diabetes and cardiovascular diseases. This information will be of interest to both ordinary patients and those with medical background, including practicing urologists.<br \/>\nThe complete text of the article is available <a href=\"http:\/\/www.kalofagas.ca\/brief-overview-of-what-you-can-do-on-the-website\/\">HERE<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The site ww.cialweb.com presents a new article dedicated to the issue of prescribing phosphodiesterase type 5 inhibitors against erectile dysfunction (ED) for patients with cardiovascular diseases. In this large study, the papers of Shabber Abbas, BS, and Jacqueline Lanoix, PhD were used. Dr. Nehra, a consultant for the pharmaceutical concern Pfizer, left his notes about this study. The article contains detailed consideration of the intake of PDE-5 inhibitors against ED in patients with hypertension, dyslipidemia,&#8230; <a class=\"moretag\" href=\"https:\/\/www.ackc.org\/jayedit\/for-patients-with-cardiovascular-diseases\/\">More \u2192<\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[],"tags":[],"class_list":["post-4378","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/posts\/4378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/comments?post=4378"}],"version-history":[{"count":0,"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/posts\/4378\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/media?parent=4378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/categories?post=4378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ackc.org\/jayedit\/wp-json\/wp\/v2\/tags?post=4378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}